An association of losartan-hydrochlorothiazide, but not losartan-furosemide, completely arrests progressive injury in the remnant kidney

American Journal of Physiology - Renal Physiology

Volumn 310, Issue 2, 2015, Pages F135-F143

  Alarcon Arias, Simone Costa ^a   Souza, Renata Alves ^a   Avancini Costa Malheiros, Denise Maria ^a   Fanelli, Camilla ^a   Fujihara, Clarice Kazue ^a   Zatz, Roberto ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

5 6 nephrectomy; Chronic kidney disease; Furosemide; Thiazides

Indexed keywords

ALBUMIN; ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; CREATININE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; LOSARTAN; LOSARTAN POTASSIUM; DRUG COMBINATION; HYDROCHLOROTHIAZIDE, LOSARTAN DRUG COMBINATION;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BODY WEIGHT; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG TREATMENT FAILURE; FIBROSING ALVEOLITIS; GLOMERULOSCLEROSIS; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY INJURY; KIDNEY MASS; MACROPHAGE MIGRATION; MALE; MONOTHERAPY; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL PROTECTION; ANIMAL; BLOOD PRESSURE; DRUG COMBINATION; DRUG EFFECTS; KIDNEY; KIDNEY CIRCULATION; WISTAR RAT;

ALBUMINURIA; ANIMALS; BLOOD PRESSURE; DRUG COMBINATIONS; FUROSEMIDE; HYDROCHLOROTHIAZIDE; HYPERTENSION; KIDNEY; LOSARTAN; MALE; RATS; RATS, WISTAR; RENAL CIRCULATION;

EID: 84955270836     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00388.2015     Document Type: Article

References (50)

1. Abe M, Okada K, Maruyama T, Matsumoto K. Antiproteinuric and blood pressure-lowering effects of a fixed-dose combination of losartan and hydrochlorothiazide in hypertensive patients with stage 3 chronic kidney disease. Pharmacotherapy 29: 1061-1072, 2009.
2. Abe M, Okada K, Maruyama T, Matsumoto K. Renoprotect and blood pressure lowering effect of low-dose hydrochlorothiazide added to intensive renin-angiotensin inhibition in hypertensive patients with chronic kidney disease. Int J Clin Pharmacol Ther 47: 525-532, 2009.
3. Acchiardo SR, Skoutakis VA. Clinical efficacy, safety, and pharmacokinetics of indapamide in renal impairment. Am Heart J 106: 237-244, 1983.
4. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77: 1993-2000, 1986.
5. Arias SC, Valente CP, Machado FG, Fanelli C, Origassa CS, de Brito T, Camara NO, Malheiros DM, Zatz R, Fujihara CK. Regression of albuminuria and hypertension and arrest of severe renal injury by a losartan-hydrochlorothiazide association in a model of very advanced nephropathy. PLos One 8: e56215, 2013.
6. Calder JA, Schachter M, Sever PS. Direct vascular actions of hydrochlorothiazide and indapamide in isolated small vessels. Eur J Pharmacol 220: 19-26, 1992.
7. Calder JA, Schachter M, Sever PS. Ion channel involvement in the acute vascular effects of thiazide diuretics and related compounds. J Pharmacol Exp Ther 265: 1175-1180, 1993.
8. Areceptor blockade increases renoprotection provided by renin-angiotensin system blockade in 5/6 nephrectomized Ren-2 transgenic rats. Life Sci 118: 297-305, 2014.
9. Chan CY, Peterson EJ, Ng TM. Thiazide diuretics as chronic antihypertensive therapy in patients with severe renal disease-is there a role in the absence of diuresis? Ann Pharmacother 46: 1554-1558, 2012.
10. Cirillo M, Marcarelli F, Mele AA, Romano M, Lombardi C, Bilancio G. Parallel-group 8-week study on chlorthalidone effects in hypertensives with low kidney function. Hypertension 63: 692-697, 2014.
11. Coltamai L, Maillard M, Simon A, Vogt B, Burnier M. Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans. J Hypertens 28: 520-526, 2010.
12. Daniels BS, Hostetter TH. Adverse effects of growth in the glomerular microcirculation. Am J Physiol Renal Fluid Electrolyte Physiol 258: F1409-F1416, 1990.
13. Dussol B, Moussi-Frances J, Morange S, Somma-Delpero C, Mundler O, Berland Y. A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease. J Clin Hypertens (Greenwich) 14: 32-37, 2012.
14. Dussol B, Moussi-Frances J, Morange S, Somma-Delpero C, Mundler O, Berland Y. A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension. Nephrol Dial Transplant 20: 349-353, 2005.
15. Floege J, Burns MW, Alpers CE, Yoshimura A, Pritzl P, Gordon K, Seifert RA, Bowen-Pope DF, Couser WG, Johnson RJ. Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. Kidney Int 41: 297-309, 1992.
16. Fujihara CK, Malheiros DM, Zatz R. Losartan-hydrochlorothiazide association promotes lasting blood pressure normalization and completely arrests long-term renal injury in the 5/6 ablation model. Am J Physiol Renal Physiol 292: F1810-F1818, 2007.
17. Fujihara CK, Malheiros DM, Zatz R, Noronha IL. Mycophenolate mofetil attenuates renal injury in the rat remnant kidney. Kidney Int 54: 1510-1519, 1998.
18. Fujisaki K, Tsuruya K, Nakano T, Taniguchi M, Higashi H, Katafuchi R, Kanai H, Nakayama M, Hirakata H, Kitazono T. Impact of combined losartan/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension. Hypertens Res 37: 993-998, 2014.
19. Ganado P, Ruiz E, Del Rio M, Larcher F, Sanz M, Steinert JR, Tejerina T. Growth inhibitory activity of indapamide on vascular smooth muscle cells. Eur J Pharmacol 428: 19-27, 2001.
20. Harris RC, Haralson MA, Badr KF. Continuous stretch-relaxation in culture alters rat mesangial cell morphology, growth characteristics, and metabolic activity. Lab Invest 66: 548-554, 1992.
21. Hoshino T, Ookawara S, Miyazawa H, Ito K, Ueda Y, Kaku Y, Hirai K, Mori H, Yoshida I, Tabei K. Renoprotective effects of thiazides combined with loop diuretics in patients with type 2 diabetic kidney disease. Clin Exp Nephrol 19: 247-253, 2015.
22. Ijpelaar DH, Schulz A, Koop K, Schlesener M, Bruijn JA, Kerjaschki D, Kreutz R, de Heer E. Glomerular hypertrophy precedes albuminuria and segmental loss of podoplanin in podocytes in Munich-Wistar-Fromter rats. Am J Physiol Renal Physiol 294: F758-F767, 2008.
23. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311: 507-520, 2014.
24. Jepsen FL, Mortensen PB. Interstitial fibrosis of the renal cortex in minimal change lesion and its correlation with renal function. A quantitative study. Virchows Arch A Pathol Anat Histol 383: 265-270, 1979.
25. Jones B, Nanra RS. Double-blind trial of antihypertensive effect of chlorothiazide in severe renal failure. Lancet 2: 1258-1260, 1979.
26. Karadsheh F, Weir MR. The use of thiazides in chronic kidney disease. Curr Hypertens Rev 10: 81-85, 2014.
27. Karalliedde J, Maltese G, Hill B, Viberti G, Gnudi L. Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria. Clin J Am Soc Nephrol 8: 1899-1905, 2013.
28. Kidney Disease Outcomes Quality Initiative. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43: S1-S290, 2004.
29. Klahr S, Schreiner G, Ichikawa I. The progression of renal disease. N Engl J Med 318: 1657-1666, 1988.
30. Kuriyama S, Otsuka Y, Ueda H, Sugano N, Yoshizawa T, Yamada T, Hosoya T. Augmented antihypertensive effect of a fixed combination formula of candesartan and hydrochlorothiazide combined with furosemide in a patient on peritoneal dialysis. Clin Exp Nephrol 15: 175-178, 2011.
31. Lafayette RA, Mayer G, Park SK, Meyer TW. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 90: 766-771, 1992.
32. Lane PH. Furosemide treatment, angiotensin II, and renal growth and development in the rat. Pediatr Res 37: 747-754, 1995.
33. Lane PH, Tyler LD, Schmitz PG. Chronic administration of furosemide augments renal weight and glomerular capillary pressure in normal rats. Am J Physiol Renal Physiol 275: F230-F234, 1998.
34. Mann B, Hartner A, Jensen BL, Kammerl M, Kramer BK, Kurtz A. Furosemide stimulates macula densa cyclooxygenase-2 expression in rats. Kidney Int 59: 62-68, 2001.
35. Musini VM, Nazer M, Bassett K, Wright JM. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev 5: CD003824, 2014.
36. Pickkers P, Hughes AD, Russel FG, Thien T, Smits P. Thiazideinduced vasodilation in humans is mediated by potassium channel activation. Hypertension 32: 1071-1076, 1998.
37. Reubi FC, Cottier PT. Effects of reduced glomerular filtration rate on responsiveness to chlorothiazide and mercurial diuretics. Circulation 23: 200-210, 1961.
38. Rodriguez-Iturbe B, Pons H, Quiroz Y, Gordon K, Rincon J, Chavez M, Parra G, Herrera-Acosta J, Gomez-Garre D, Largo R, Egido J, Johnson RJ. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure. Kidney Int 59: 2222-2232, 2001.
39. Rubin AA, Roth FE, Winbury MM. A non-diuretic benzothiadiazine with anti-hypertensive properties. Nature 192: 176-177, 1961.
40. Schreiner GE. Chlorothiazide in renal disease. Ann NY Acad Sci 71: 420-429, 1958.
41. Shi Y, Wang X, Chon KH, Cupples WA. Tubuloglomerular feedbackdependent modulation of renal myogenic autoregulation by nitric oxide. Am J Physiol Regul Integr Comp Physiol 290: R982-R991, 2006.
42. Shiga Y, Miura S, Mitsutake R, Norimatsu K, Nagata I, Arimura T, Shimizu T, Morii J, Kuwano T, Uehara Y, Inoue A, Shirotani T, Fujisawa K, Matsunaga E, Saku K. Efficacy and safety of a single-pill fixed-dose combination of high-dose telmisartan/hydrochlorothiazide in patients with uncontrolled hypertension. J Renin Angiotensin Aldosterone Syst 13: 394-400, 2012.
43. Shimaji H, Shirahase H, Morishita S, Osumi S. Effect of indapamide on the proliferation of Balb/C 3T3 cells induced by platelet-derived growth factor. Jpn J Pharmacol 57: 609-612, 1991.
44. Sinnakirouchenan R, Kotchen TA. Role of sodium restriction and diuretic therapy for "resistant" hypertension in chronic kidney disease. Semin Nephrol 34: 514-519, 2014.
45. Tilstone WJ, Fine A. Furosemide kinetics in renal failure. Clin Pharmacol Ther 23: 644-650, 1978.
46. Wallenstein S, Zucker CL, Fleiss JL. Some statistical methods useful in circulation research. Circ Res 47: 1-9, 1980.
47. Woodman R, Brown C, Lockette W. Chlorthalidone decreases platelet aggregation and vascular permeability and promotes angiogenesis. Hypertension 56: 463-470, 2010.
48. Wright FS, Schnermann J. Interference with feedback control of glomerular filtration rate by furosemide, triflocin, and cyanide. J Clin Invest 53: 1695-1708, 1974.
49. 1-receptor blocker over thiazide alone on renoprotection in LNAME/SHR. Am J Physiol Renal Physiol 289: F871-F879, 2005.
50. Zhu Z, Zhu S, Liu D, Cao T, Wang L, Tepel M. Thiazide-like diuretics attenuate agonist-induced vasoconstriction by calcium desensitization linked to Rho kinase. Hypertension 45: 233-239, 2005.